About Membrane-bound ghrelin O-acyltransferase MBOAT4
Membrane-bound ghrelin O-acyltransferase MBOAT4 (MBOAT4) is a protein
from Homo sapiens identified by UniProt accession
Q96T53, 435 residues long.
MolForge cross-references it against 0 known binders and
113 disease associations.
Target properties
| Protein name | Membrane-bound ghrelin O-acyltransferase MBOAT4 |
| UniProt accession | Q96T53 |
| Gene | MBOAT4 |
| Organism | Homo sapiens |
| Length | 435 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (113)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.29
- endometrial cancer · score 0.18
- grip strength measurement · score 0.18
- bone density · score 0.17
- bone measurement · score 0.16
- balding measurement · score 0.14
- hair shape measurement · score 0.12
- BMI-adjusted waist circumference · score 0.11
- FEV/FVC ratio · score 0.11
- mental or behavioural disorder · score 0.10
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96T53-F1 | alphafold | PREDICTED | 88.68 | — |
Amino-acid sequence (435 residues)
MEWLWLFFLH PISFYQGAAF PFALLFNYLC IMDSFSTRAR YLFLLTGGGA LAVAAMGSYA VLVFTPAVCA VALLCSLAPQ QVHRWTFCFQ MSWQTLCHLG LHYTEYYLHE PPSVRFCITL SSLMLLTQRV TSLSLDICEG KVKAASGGFR SRSSLSEHVC KALPYFSYLL FFPALLGGSL CSFQRFQARV QGSSALHPRH SFWALSWRGL QILGLECLNV AVSRVVDAGA GLTDCQQFEC IYVVWTTAGL FKLTYYSHWI LDDSLLHAAG FGPELGQSPG EEGYVPDADI WTLERTHRIS VFSRKWNQST ARWLRRLVFQ HSRAWPLLQT FAFSAWWHGL HPGQVFGFVC WAVMVEADYL IHSFANEFIR SWPMRLFYRT LTWAHTQLII AYIMLAVEVR SLSSLWLLCN SYNSVFPMVY CILLLLLAKR KHKCN
Explore Membrane-bound ghrelin O-acyltransferase MBOAT4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets